
Bridging Therapy Considerations in DLBCL Before CAR T-Cell Therapy
In this segment, Dr. Caron A. Jacobson discusses selecting bridging therapies for patients with DLBCL awaiting CAR T-cell therapy, including the role of radiotherapy and medications to avoid.
Episodes in this series
In this segment, Dr. Caron A. Jacobson discusses selecting bridging therapies for patients with DLBCL awaiting CAR T-cell therapy, including the role of radiotherapy and medications to avoid. She identifies radiotherapy as her preferred bridging approach when feasible, particularly for patients with a single disease site where treatment can be delivered with acceptable toxicity. Its limited overlap with CAR T-cell therapy toxicities and potential for synergistic activity support its use in selected patients. Dr. Jacobson also cautions against bendamustine because of its lymphotoxic effects, which can contribute to profound lymphopenia, myelosuppression, and infection risk, particularly when followed by lymphodepleting chemotherapy. She discusses the potential role of bispecific antibodies as bridging therapy after leukapheresis, noting their promising response rates in patients with chemotherapy-refractory disease. Finally, she addresses the timing of CD19-targeted therapies before CD19-directed CAR T-cell therapy, emphasizing the need to consider an appropriate washout period for agents such as tafasitamab to reduce potential interference with CAR T-cell recognition.
Related to this article








